Medication Growth Following Diagnosis of Intellectual and Developmental Disabilities at Varying Ages Throughout Childhood Authors: Robert B Christian, Izabela E Annis, Neal A deJong, Scott A Davis, Phillip M Hughes, Kathleen C Thomas Published: 2026 ABSTRACT ABSTRACTPurposeTo characterize age‐related trajectories in psychotropic medication and polypharmacy use among children newly diagnosed with intellectual and developmental disabilities (IDD), addressing an evidence gap in longitudinal prescribing patterns.MethodsThis study uses a retrospective longitudinal cohort design and commercial insurance claims from the southeast (2011–2021) to study children newly diagnosed with IDD, aged 2–17 years (N = 938). Psychotropic medication use was defined as ≥ 1 prescription fill per year; polypharmacy as ≥ 2 classes used concurrently for ≥ 60 days. Generalized linear mixed models with natural cubic splines describe longitudinal growth trajectories as a function of age at first IDD diagnosis and follow‐up year, adjusting for gender, cohort year and region of residence.ResultsWithin 3 years of diagnosis, 40.1% of children initiated psychotropic medication, and 9.4% experienced sustained polypharmacy. Medication use increased with each follow‐up year among children diagnosed before age 12. For example, children diagnosed at age 2 had a 2.34‐fold increase in medication use by year 3 versus year 1 (95% CI: 1.56–3.53) and nearly a sixfold increase in polypharmacy (OR = 5.89; 95% CI: 2.89–11.99). In contrast, children diagnosed during adolescence showed higher initial use but minimal growth. Psychiatric comorbidities also increased with time, particularly among younger children.ConclusionChildren diagnosed with IDD at younger ages experience steep increases in psychotropic medication use over time, including sustained exposure to polypharmacy. Additional research on long‐term benefits and harms of psychiatric medication use is needed.Keywords: children and adolescents, intellectual and developmental disorders, pediatric psychopharmacology, psychopharmacology and polypharmacy trends Introduction Intellectual and developmental disabilities (IDD) are a diverse group of chronic conditions that typically begin in childhood and affect intellectual functioning and adaptive behaviors. Definition of IDD includes autism spectrum disorders and related conditions, genetic and chromosomal conditions, neurological and developmental delays and intellectual disabilities [1]. Recent evidence on psychotropic medication use in children with IDD varies by condition group and year. In a national commercially insured cohort of children with autism spectrum disorder and 3 years enrollment, 2016–2023, psychotropic medication use showed increasing use by age group at year 1 (0.9% among children aged 0–4, 32.8% among children aged 10–17). From year 1 to year 3, medication use increased in younger children but declined in the oldest group [2]. In a cross‐sectional analysis 2015–2019, 55% of children with IDD were treated with at least one psychotropic medication and 26% used two or more [1]. A meta‐analysis through 2015 of youth with autism indicated 17% were treated with antipsychotic medications [3]. A retrospective cohort analysis of children with Down Syndrome 2010–2013 indicated that children aged 5–11 were less likely to be treated with a psychotropic medication than those aged 12–27 (17% vs. 25%) while for younger children only, modeling indicated that the odds of psychotropic medication use increased for each increasing year of age [4]. In a sample of adults with attention deficit hyperactivity disorder (ADHD) and IDD from 2015 to 2018, 50% were treated with antipsychotic medications [5]. Guidelines recommend treatment with psychosocial services and psychotropic medications to target psychiatric disorders or symptoms for children with IDD [6]. If a child does not respond, guidelines recommend switching or combining medications [7]. But diagnosis of psychiatric conditions is difficult in children with IDD, making monitoring challenging [6, 7, 8]. While guidelines indicate short‐term treatment with psychotropic medications, clinicians are hampered by a lack of guidance and training on strategies for deprescribing [9, 10, 11]. In order to identify which children and adolescents with IDD can benefit from medication and which need less, clinicians and families need a baseline understanding of patterns of medication use as children age. This study addresses this gap, using 9 years of claims data. This study provides a longitudinal analysis of psychotropic medication treatment trajectories among children newly diagnosed with IDD by age of diagnosis and follow‐up year. Methods Data We used data from a large commercial insurer in the southeast 2011–2021. While the insurer is located in the southeast, the plan also covers individuals who do not physically live in the southeast. This database contains deidentified outpatient, inpatient, prescription claims and enrollment files with records from insured groups, administrative services only groups, and individual market and Affordable Care Act Exchange Plans. Racial and ethnic data are not available in the database. This study was deemed exempt from oversight by the Institutional Review Board of the University of North Carolina at Chapel Hill because it involves secondary analyses of existing deidentified data. The study cohort included children newly diagnosed with IDD, aged 2–17 years at the time of their first, observed IDD diagnosis (index date). We required at least 12 months of continuous enrollment prior to index date (baseline period) to ascertain that the child had received no prior IDD diagnosis. To identify children with IDD we used International Classification of Diseases, Ninth/Tenth Revisions [ICD‐9/10] codes as outlined in the algorithm by Lin [12]. To characterize the trajectory of new treatment of IDD, we also limited the cohort to patients with no psychotropic medication use in the baseline period. Lastly, we required 3 years of continuous enrollment (follow‐up period) post index date. Figure S1 presents the cohort selection process. To understand the trajectory of psychotropic medication use beyond the initial 3 years post IDD diagnosis, we assembled a secondary cohort of children with 5 years of continuous enrollment post index date. Measures To obtain a longitudinal view of a child's psychotropic medication use, we divided the follow‐up period into three 1‐year periods yielding three repeated outcome measures for each child. We defined two binary outcomes of interest: (1) whether a child had any psychotropic medication use and (2) whether a child had at least one episode of psychotropic polypharmacy. We used pharmacy claims to identify psychotropic medications. Using National Drug Codes and generic drug names, we classified psychotropic medications into nine classes: antidepressants, antipsychotics, anxiolytics, stimulants, atomoxetine, α‐agonists, anticonvulsants, lithium, and insomnia medications [13]. Benzodiazepines and anticonvulsants were considered “psychotropic” if the child had no diagnosis of seizure or epilepsy. Psychotropic medication use was defined as having at least one prescription fill for at least one psychotropic medication during the follow‐up year. Use of psychotropic polypharmacy was defined as having at least two prescription fills for at least two different classes of psychotropic medications that, if taken as directed, would be used concurrently for at least 60 days [14]. Episodes of polypharmacy were identified using prescription fill date and days' supply by constructing a “supply diary” for each child [1]. The diary contained indicators of whether each psychotropic medication class was available on each day of each of the follow‐up years to the child. The diary was adjusted for hospitalizations such that if an inpatient stay occurred during a fill, the length of stay was added to the total days' supply, assuming that the medication was administered to the child in the hospital and the child continued medication use after discharge. In sensitivity analyses, study outcomes were constructed in a parallel manner and extended to 5 years of follow‐up data. Using enrollment data files, we constructed variables for covariates: age group, gender, year of cohort entry and region of residence. We also identified psychiatric conditions using ICD‐9/10 codes [15, 16, 17, 18]. See the Supporting Information for further details on measurement. Analyses We used descriptive statistics to describe the study cohort. We calculated the prevalence of psychiatric conditions in the baseline and in the entire 3‐year follow‐up period. Prevalence of psychotropic medication use was summarized for each of the follow‐up years. We used generalized linear mixed models to describe longitudinal growth trajectories of our two outcomes as a function of age at the time of first IDD diagnosis and follow‐up year. The models were adjusted for gender, year of cohort entry and region of residence. We did not control for presence of psychiatric conditions in the follow‐up years, as we anticipated that progression of psychotropic medication use would correlate with the accumulation of psychiatric diagnoses for a child. We used natural cubic splines to characterize the relationship between age at IDD diagnosis and outcomes [19]. Further, we assumed that effect of age might vary depending on the follow‐up year and captured this relationship through inclusion of an interaction term between the age trend and each of the follow‐up years [20]. We modeled the correlated nature of our data, repeated outcome measurements, through specification of the first‐order autoregressive covariance structure. We used the models to estimate odds ratios and corresponding 95% confidence intervals. Through use of predictive margins, we estimated predicted probabilities of psychotropic medication use and psychotropic polypharmacy use at each level of age at IDD diagnosis and follow‐up year. In sensitivity analyses, we calculated descriptive statistics and prevalence measures for children in the secondary cohort. We used SAS version 9.4 (SAS Institute, Cary, NC) to conduct all statistical analyses. Results Our study cohort included 938 children with a mean age at the time of index IDD diagnosis of 8.8 years (standard deviation [SD] = 4.3, Table 1). The majority of children (73.5%) were diagnosed with at least one psychiatric condition during the entire study period that included the 1‐year baseline and 3‐years of follow‐up. The most frequent psychiatric diagnoses were anxiety and trauma‐related disorders (36.4%), and attention deficit disorder (32.4%). Prevalence of all psychiatric conditions grew considerably between the baseline period and follow‐up years. For example, the proportion of children diagnosed with attention deficit disorder grew from 7.4% in the baseline period to 30.9% in the follow‐up years. The number of psychiatric conditions diagnosed in children also increased over time (Table S1). For example, among children aged 6–12 years, the proportion with one or more psychiatric diagnoses increased from 36.8% in the baseline period to 68.7% in the follow‐up years. TABLE 1Cohort characteristics of children newly diagnosed with intellectual and developmental disabilities, stratified by baseline period, follow‐up period and overall (baseline and follow‐up combined), N = 938, N (%).CharacteristicBaseline periodFollow‐up periodBaseline or follow‐up N % N % N %Age group2–527529.36–1243246.113–1723124.6GenderFemale22824.3Male71075.7Cohort entry year201221823.2201315917.0201413414.3201512012.8201610511.2201711612.42018869.2State of residenceNorth Carolina81386.7Virginia171.8South Carolina111.2Florida141.5Other states838.8RegionNorth Carolina81386.7South census region (excluding North Carolina)606.4Northeast/Midwest/West656.9Any psychiatric diagnosis39842.465169.468973.5Major depressive and other depressive disorders202.1667.0747.9Other mood disorders——495.2505.3Developmental delays20622.030532.534536.8Anxiety and trauma‐related disorders11512.331733.834136.4Attention deficit disorder697.429030.930432.4Conduct and oppositional defiant disorders212.2576.1656.9Impulse control242.6394.2525.5Disturbance of emotions in childhood and adolescence111.2——171.8Sleep disorders161.7909.69710.3Other mental disorders212.2879.39810.4Substance use disorder——111.2131.4 Note: — Values are not reportable due to small cell sizes. Baseline period = 12 months prior to index IDD diagnosis, follow‐up period = 3 years post index IDD diagnosis. Cohort characteristics of children newly diagnosed with intellectual and developmental disabilities, stratified by baseline period, follow‐up period and overall (baseline and follow‐up combined), N = 938, N (%). Note: — Values are not reportable due to small cell sizes. Baseline period = 12 months prior to index IDD diagnosis, follow‐up period = 3 years post index IDD diagnosis. Forty percent of children were prescribed psychotropic medications at some point during the 3‐year follow‐up period (Figure 1, Table S2). The most frequently utilized medications were ADHD medications (26.1%) and antidepressants (16.3%). The relatively high proportion of ADHD medication use was attributable to stimulants (21.2%). Almost 18% of children were dispensed medications from two or more psychotropic medication classes during at least one of the three follow‐up years. Overall, 9.4% of children experienced sustained psychotropic polypharmacy throughout the entire follow‐up period. We noted increases in the prevalence of use of almost all medication classes across the follow‐up years. Notably, overall use of ADHD medications increased from 14.9% in year 1 to 20.9% in year 3; use of antidepressants increased from 8.0% to 12.8%. Use of psychotropic medications and psychotropic polypharmacy in year 1, 2, and 3 after incident IDD diagnosis. ADD Rx: Attention deficit disorder medication, Any Rx: Any psychotropic medication, IDD: Intellectual and developmental disabilities, Insomnia Rx: Insomnia medication, PP: Psychotropic polypharmacy, Psych Rx: Psychotropic medication. The probability of psychotropic medication use increased with each follow‐up year for children newly diagnosed with IDD at age 2–11 (Figure 2, Table 2). For children diagnosed at age 12 or 13, this probability increased in year 3. Conversely, children diagnosed at age 14 or older had no increases in probability of psychotropic medication use across the follow‐up years. For instance, even though the youngest children, diagnosed at age 2, had the lowest probability of receiving any psychotropic medication in the first year, their odds of psychotropic medication use increased by 1.65 (odds ratio [OR] = 1.65, 95% confidence interval [CI]: 1.14–2.41) in year 2 and by 2.34 in year 3 (CI: 1.56–3.53) as compared to first follow‐up year. Comparatively, children diagnosed at age 9 had one of the highest overall uses of psychotropic medications in follow‐up years, but their odds of psychotropic medication use in year 2 increased by 1.29 (CI: 1.06–1.57) and 1.43 (CI: 1.15–1.78) in year 3. Finally, the oldest children, those diagnosed at age 18, did not experience increases in probability of psychotropic medication use over the years (year 2 OR = 0.87, CI: 0.59–1.28; year 3 OR = 0.98, CI: 0.64–1.50). Probability of use any psychotropic medication and psychotropic polypharmacy by age at IDD diagnosis and year 1, 2 and 3 post incident IDD diagnosis adjusted for gender, region, and year of cohort entry. Each numbered line represents individuals diagnosed with IDD at a specific age noted at the top of the line. The starting point of each line represents the probability of use at the follow‐up year 1. The end point of each line represents the probability of use at follow‐up year 3. Each line shows how predicted probability of use changes as individuals (diagnosed with IDD at a specific age) get older. TABLE 2Parameter estimates, odds ratios and 95% confidence intervals from generalized linear mixed models assessing the effect of age at incident IDD diagnosis and follow‐up year on the outcome among children newly diagnosed with intellectual and developmental disabilities.OutcomesAny psychotropic medicationPsychotropic polypharmacyEffectOR95% CI P OR95% CI P Age 2: FU Year 21.651.14–2.410.00873.451.46–8.120.0047Age 2: FU Year 32.341.56–3.53< 0.00015.892.89–11.99< 0.0001Age 3: FU Year 21.601.18–2.160.00233.171.46–6.870.0035Age 3: FU Year 32.171.57–3.01< 0.00015.252.76–9.99< 0.0001Age 4: FU Year 21.551.22–1.950.00032.911.46–5.830.0025Age 4: FU Year 32.021.56–2.60< 0.00014.692.63–8.35< 0.0001Age 5: FU Year 21.491.24–1.79< 0.00012.681.44–4.980.0018Age 5: FU Year 31.871.53–2.28< 0.00014.182.50–7.00< 0.0001Age 6: FU Year 21.441.23–1.70< 0.00012.461.42–4.280.0014Age 6: FU Year 31.741.45–2.08< 0.00013.732.36–5.91< 0.0001Age 7: FU Year 21.391.17–1.660.00022.271.38–3.710.0012Age 7: FU Year 31.621.33–1.96< 0.00013.332.21–5.02< 0.0001Age 8: FU Year 21.341.10–1.630.00312.081.33–3.270.0014Age 8: FU Year 31.521.22–1.880.00022.972.05–4.31< 0.0001Age 9: FU Year 21.291.06–1.570.01141.921.25–2.930.0028Age 9: FU Year 31.431.15–1.780.00122.651.87–3.76< 0.0001Age 10: FU Year 21.241.03–1.490.02271.761.16–2.680.0084Age 10: FU Year 31.371.11–1.670.00262.371.68–3.33< 0.0001Age 11: FU Year 21.181.01–1.400.04311.621.04–2.510.0312Age 11: FU Year 31.311.09–1.570.00392.111.48–3.01< 0.0001Age 12: FU Year 21.130.97–1.330.11521.490.93–2.400.1008Age 12: FU Year 31.251.05–1.490.01041.881.28–2.760.0012Age 13: FU Year 21.080.92–1.280.34351.370.81–2.330.2433Age 13: FU Year 31.201.00–1.450.05131.681.10–2.570.0165Age 14: FU Year 21.040.85–1.260.71301.260.70–2.280.4451Age 14: FU Year 31.150.93–1.440.19631.500.93–2.410.0949Age 15: FU Year 20.990.78–1.260.95281.160.60–2.250.6645Age 15: FU Year 31.110.85–1.440.44341.340.78–2.280.2846Age 16: FU Year 20.950.71–1.260.72301.070.51–2.240.8674Age 16: FU Year 31.060.78–1.450.70111.190.66–2.170.5601Age 17: FU Year 20.910.65–1.270.57520.980.43–2.240.9610Age 17: FU Year 31.020.71–1.480.91431.070.55–2.070.8513Age 18: FU Year 20.870.59–1.280.47880.900.36–2.240.8220Age 18: FU Year 30.980.64–1.500.92350.950.46–1.980.8925 Note: Adjusted for gender, region and cohort year.Abbreviations: CI, confidence interval; FU, follow‐up; OR, odds ratio. Parameter estimates, odds ratios and 95% confidence intervals from generalized linear mixed models assessing the effect of age at incident IDD diagnosis and follow‐up year on the outcome among children newly diagnosed with intellectual and developmental disabilities. Note: Adjusted for gender, region and cohort year. Abbreviations: CI, confidence interval; FU, follow‐up; OR, odds ratio. Similarly, the age of IDD diagnosis had a large effect on the use of psychotropic polypharmacy. The probability of psychotropic polypharmacy use grew with each follow‐up year for children diagnosed with IDD at age 2–11. Even though the youngest children had the lowest probability of receiving polypharmacy in year 1, their odds increased over 3‐fold in year 2 (OR = 3.45, CI: 1.46–8.12) and almost 6‐fold in year 3 (OR = 5.89, CI: 2.89–11.99). In comparison, children diagnosed with IDD later (age 16–18) experienced no growth in psychotropic polypharmacy use over time and their probabilities over the span of the three follow‐up years, on average, were similar or lower than probabilities of children diagnosed at age 2–11 in year 2 and year 3. Three years after the IDD diagnosis, children diagnosed at the youngest age had the highest probability of psychotropic polypharmacy use, while children diagnosed at 18 had the lowest probability of receiving psychotropic polypharmacy. Sixty percent of children diagnosed with IDD at age 2–5 also had a diagnosis of at least one psychiatric condition at baseline and 78.5% received at least one diagnosis in the follow‐up period (Table S1). In contrast, among children diagnosed at age 6–12, the prevalence of at least one psychiatric condition at baseline was 36.8% and 68.8% in follow‐up years. Among children diagnosed at age 13–17, the prevalence of at least one psychiatric condition was 32.0% at baseline and 59.7% in follow‐up years. Descriptive analyses of the cohort of children newly diagnosed with IDD who also had 5 years of continuous enrollment (N = 448) revealed that the prevalence of psychiatric conditions in the 5‐year follow‐up period was comparable to that among children with 3 years of continuous enrollment (Table S3). The long‐term trends in the use of psychotropic medications among children with 5 years of continuous enrollment varied depending on medication class (Table S4). Notably, there was steady and sustained growth in the prevalence of psychotropic polypharmacy, increasing from 3.8% in year 1 to 8.7% in year 3, and 9.2% in year 5. Discussion This work characterizes psychotropic medication usage patterns over time in an incident cohort of children with IDD using novel methods of evaluation and data visualization. One key finding was that younger children newly diagnosed with IDD were less likely to use psychotropic medication in the first year after an IDD diagnosis, but their probability of use increased rapidly thereafter. In contrast, IDD diagnosis in adolescence was associated with higher probability of psychotropic medication usage in the initial year after diagnosis and little to no change in the probability of use over time. These trends are similar to findings from age group cohorts of children with autism spectrum disorder and Down Syndrome [2, 4]. Our analysis by age of diagnosis indicates that children diagnosed around the time of middle school, aged 9–12, had the highest probability of psychotropic medication use in the year after IDD diagnosis. Children's experience of psychotropic polypharmacy grew with each follow‐up year for children diagnosed with IDD through age 11. These findings provide a meaningful and novel benchmark for psychotropic prescribing experienced by children newly diagnosed with IDD. That younger children are initially lower users of psychotropic medication is reassuring. This may be a general reflection of the cautious prescribing behavior of providers treating young children. However, the relatively rapid uptake of psychotropics in subsequent years for these young children raises questions that could be important for clinical care. Future research should examine if young children with IDD who start medication treatment early taper off and come to look like the adolescent group over time or are a higher complexity group that will go on to be among the highest utilizers in adolescence and adulthood. This might indicate that such a group could benefit from targeted rapid access to non‐medical/behavioral therapies. Early access to behavioral intervention has been associated with improved outcomes in controlled studies and community settings [21]. However, in the current practice environment in the IDD realm, it is well recognized that delays in access to non‐medical therapies such as respite care or applied behavioral analysis remain an unresolved dilemma [22]. Little is known about the relationship between early behavioral therapy access and later medication burden, but this is an important area of study with large implications for informing policy and practice in the IDD space. Future research on long‐term benefits and harms of psychiatric medication use is needed to determine if young high utilizers would benefit from policies designed to curb potentially inappropriate prescribing or polypharmacy over time. Future work should also examine if groups with later IDD diagnosis remain relatively stable utilizers or become relatively high utilizers in adulthood. A first diagnosis of IDD in adolescence suggests mild IDD, consistent with little change in psychotropic medication use over time in these findings. However, research should explore the role of psychiatric co‐morbidity over time, known to peak in early adulthood [23, 24, 25]. This study is limited by the length of time children in our cohort met eligibility criteria for continuous enrollment, in this case 3 or 5 years. These data are therefore unable to demonstrate outcomes of longer‐term accumulation of time on psychiatric medication or numbers of psychotropic medications. However, the methods and findings are valuable for evaluating and visualizing medication utilization trends over time. Chan and colleagues also limited their cohort analysis to 3 years suggesting that this may be a limitation of claims data subject to churn [2]. Other analyses examine medication use with all‐payer claims or electronic health records but usually children are analyzed irrespective of the timing of their incident diagnosis, which allows examination of a larger number of years, but not how trends reflect age at first diagnosis [4, 26, 27]. Future iterations of this work will benefit from study designs that support longer periods of follow‐up. In addition, future work should explore parent‐ and youth‐reported outcomes [28]. This will require linking administrative and clinical data with survey data from parents and youth, to combine clinical detail on psychotropic medication prescribing with family perspectives. Regulatory affairs and human research ethics bodies must develop standards that support inclusion of people with IDD who may not be able to provide informed consent while also protecting confidentiality. Longitudinal data with patient‐reported outcomes are necessary to overcome the bias in psychotropic drug trial reporting associated with overestimating efficacy [29]. Such nuanced information from expanded prospective work in this realm is critical to guide both non‐medical and medication policy and treatment guidelines for children with IDD. The data presented here do not provide information on dosage of psychotropic medication and the extent to which dosage recommendations are followed. Future work would benefit from more nuanced information on presentation of concerns, the content and process of treatment decisions and associated outcomes over time. For example, detail is needed on changes in child sensitivity to psychotropic medication arising from child emotional and metabolic development, long‐term use, and accrual of larger numbers of medications over time. Data are needed that describe change in efficacy over short and long periods of time. To inform practice, detail is needed on the array of factors that may inform prescribing decisions at the patient (severity, developmental change, genetic risk factors, psychiatric and physical comorbidity), parent (distress tolerance, health literacy, navigation skill, competing caregiving demands, income, education, psychiatric and physical comorbidity), clinician (comfort prescribing psychotropic medication in general and by child age, access to medication reconciliation support), and neighborhood (access to care coordination/navigation services, mental health workforce, non‐medical support services, environmental risk factors) levels. Standards for least effective dose trials and withdrawal trials are lacking [30]. Guidance based on evidence of benefits and harms over time and heterogeneity of treatment effects of psychotropic pharmacy and polypharmacy is needed. These findings are based on 938 insured children living primarily in North Carolina. North Carolina has the second largest rural population among all states, at 33% [31]. To the extent that children in rural areas face additional barriers to care, these findings may underreport the experience of psychotropic medication for children with IDD. On the other hand, North Carolina is internationally recognized for excellence in IDD services. To the extent that children with IDD in North Carolina face greater access to IDD‐related services, these findings may overreport their experience of psychotropic medication. Future research would benefit from a larger sample of children with IDD across states. Implications for Clinical Practice One of the limitations of modern psychiatry is that diagnostic clarity is murky for younger children. In the context of IDD, this challenge is exaggerated and extends over time. The findings presented here are consistent with greater clinician comfort with prescribing as children age. Findings may also reflect greater parent comfort with trying psychotropic medication in older children. Clinicians should be aware that teens newly diagnosed with IDD likely present a different and more varied case mix compared to young children with IDD. The low rate of psychotropic polypharmacy in this group may reflect mild severity or possibly teen agency, since teens are frequently reluctant to go to the doctor or start treatment with medication [28]. Clinician awareness of parent and teen preferences is important to cultivate and may help navigating medication and non‐medical treatment decision‐making. The rapid increase in psychotropic medication use over time among children diagnosed at a young age raises a number of concerns. Behavioral therapies and non‐medical supports such as personal aides can help families to avoid behavioral crises as well as giving parents time for navigation and advocacy tasks on behalf of their child with IDD. Clinicians and policymakers should explore these options as important substitutes or complements to medication. Currently, the system of care does not move fast enough to get the full array of ideal services in place quickly when needed [32]. Psychopharmacologic layering may be a function of lack of guidance on practice, but it also comes from a desire to help quickly during crisis and a fear of regression with medication reduction. Clinicians and families should continually review the pros and cons of medication approaches as the child with IDD grows and develops. Conclusion This study characterizes psychotropic medication usage patterns over time in an understudied population of children with intellectual and developmental disabilities (IDD) using novel methods of evaluation and data visualization. Children diagnosed with IDD at a very young age appear to experience greater severity of IDD reflected in increased medication use over time. In contrast, children diagnosed with IDD as adolescents are likely mildly impaired, so although they are likely to get medication early, probability of use does not increase as they age. Funding This research was supported by the UNC Chapel Hill Eshelman School of Pharmacy and a Division of Pharmaceutical Outcomes and Policy UNC Eshelman School of Pharmacy pilot award. Dr. Hughes was funded by an Eshelman Award from the UNC Eshelman School of Pharmacy and a National Research Service Award Pre‐Doctoral Traineeship from the Agency for Healthcare Research and Quality sponsored by The Cecil G. Sheps Center for Health Services Research, The University of North Carolina at Chapel Hill, Grant No. T32‐HS000032. Ethics Statement This study was deemed exempt from oversight by the Institutional Review Board of the University of North Carolina at Chapel Hill because it involves secondary analyses of existing deidentified data. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1: Cohort selection flowchart for primary analyses of trajectories of psychotropic medication and polypharmacy use among children newly diagnosed with IDD. Table S1: Number of psychiatric conditions diagnosed at age of incident diagnosis and follow‐up period among children newly diagnosed with intellectual and developmental disabilities, stratified by age group. Table S2: Use of psychotropic medications in the follow‐up period among children newly diagnosed with IDD, N = 938 (%). Table S3: Secondary analyses. Sample characteristics of cohort of children newly diagnosed with IDD, with 5 years of continuous enrollment post IDD diagnosis, N = 448, N (%). Table S4: Secondary analyses. Use of psychotropic medications in the follow‐up period for cohort of children newly diagnosed with IDD with 5 years of follow‐up data, N = 448, N (%). Christian R. B., Annis I. E., deJong N. A., Davis S. A., Hughes P. M., and Thomas K. C., “Medication Growth Following Diagnosis of Intellectual and Developmental Disabilities at Varying Ages Throughout Childhood,” Pharmacoepidemiology and Drug Safety 35, no. 9 (2026): e70456, 10.1002/pds.70456. Previous presentation: This study was presented at the annual meeting of AcademyHealth, Baltimore, MD, July 1, 2024. Data Availability Statement The data that support the findings of this study are available from a third party commercial insurer. Restrictions apply to the availability of these data, which were used under license for this study. References Associated Data Supplementary Materials Figure S1: Cohort selection flowchart for primary analyses of trajectories of psychotropic medication and polypharmacy use among children newly diagnosed with IDD. Table S1: Number of psychiatric conditions diagnosed at age of incident diagnosis and follow‐up period among children newly diagnosed with intellectual and developmental disabilities, stratified by age group. Table S2: Use of psychotropic medications in the follow‐up period among children newly diagnosed with IDD, N = 938 (%). Table S3: Secondary analyses. Sample characteristics of cohort of children newly diagnosed with IDD, with 5 years of continuous enrollment post IDD diagnosis, N = 448, N (%). Table S4: Secondary analyses. Use of psychotropic medications in the follow‐up period for cohort of children newly diagnosed with IDD with 5 years of follow‐up data, N = 448, N (%). Data Availability Statement The data that support the findings of this study are available from a third party commercial insurer. Restrictions apply to the availability of these data, which were used under license for this study.